Kodai Capital Management LP Invests $3.52 Million in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Kodai Capital Management LP acquired 468,799 shares of BioCryst Pharmaceuticals, valued at approximately $3.5 million, increasing their stake to 0.22% of the company.
• Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals at $8.51 each, marking a 51.72% decrease in her holdings.
• Bank of America and other analysts have raised their price targets for BioCryst Pharmaceuticals, with a consensus rating of "Moderate Buy" and an average price target of $16.70.

Kodai Capital Management LP purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 468,799 shares of the biotechnology company's stock, valued at approximately $3,516,000. Kodai Capital Management LP owned about 0.22% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in BCRX. Raymond James Financial Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $80,000. Mariner LLC grew its holdings in shares of BioCryst Pharmaceuticals by 32.1% in the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 3,224 shares in the last quarter. MetLife Investment Management LLC grew its holdings in shares of BioCryst Pharmaceuticals by 6.0% in the fourth quarter. MetLife Investment Management LLC now owns 126,949 shares of the biotechnology company's stock valued at $955,000 after purchasing an additional 7,199 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of BioCryst Pharmaceuticals by 84.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 23,083 shares of the biotechnology company's stock valued at $174,000 after purchasing an additional 10,583 shares in the last quarter. Finally, Hsbc Holdings PLC grew its holdings in shares of BioCryst Pharmaceuticals by 33.9% in the fourth quarter. Hsbc Holdings PLC now owns 90,061 shares of the biotechnology company's stock valued at $677,000 after purchasing an additional 22,814 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BCRX. Royal Bank Of Canada restated an "outperform" rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Bank of America lifted their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, July 1st. Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.70.

BioCryst Pharmaceuticals Trading Down 0.8%

BCRX stock traded down $0.07 on Thursday, hitting $8.23. The company's stock had a trading volume of 582,604 shares, compared to its average volume of 3,712,292. The firm has a 50 day moving average of $8.57 and a two-hundred day moving average of $8.77. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.01 and a 1 year high of $11.31. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -45.69, a price-to-earnings-growth ratio of 1.89 and a beta of 1.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analysts' expectations of $149.59 million. The firm's revenue for the quarter was up 49.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.06) EPS. As a group, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the company's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the transaction, the director owned 65,352 shares in the company, valued at approximately $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.10% of the company's stock.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.